Sharemaestro Newsreel

Accuray names two executives to lead transformation efforts

Accuray Incorporated has announced the appointment of Todd Brown as Senior Vice President for a new Enterprise Performance Optimization organization and Sofiane Laoussadi as Senior Vice President, Global Services & Solutions. These appointments are part of the company's "Transformation Phase II" priorities, aimed at …

Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

AxoGen (NASDAQ:AXGN) EVP Marc Began Sells 67,500 Shares of Stock

AxoGen EVP Marc Began sold 67,500 shares of company stock for approximately $3.20 million, reducing his direct holdings by over 57%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, AxoGen shares rose, nearing their 52-week high, and …

AxoGen (NASDAQ:AXGN) Director Sells $646,552.26 in Stock

AxoGen Director Amy McBride Wendell sold 13,353 shares of AXGN stock for over $646,000, reducing her total holdings by 11.01%. This sale occurred under a pre-arranged Rule 10b5-1 plan, and comes as AxoGen shares traded up 2.5% to $49.67, near their 52-week high, following …

Accuray (NASDAQ: ARAY) seeks approval for $55M recapitalization, dilution and reverse split

Accuray (NASDAQ: ARAY) is seeking stockholder approval for a significant financing and recapitalization plan, including issuing $55 million in Series A Convertible Preferred Stock and warrants, and a reverse stock split. The plan aims to strengthen liquidity, reduce leverage, and achieve Nasdaq compliance, but …

FEED Looks 91.4% Undervalued on GF Value™ Despite Distressed Fundamentals

ENvue Medical Inc (NASDAQ: FEED) announced a $50 million equity facility to enhance its ENvue feeding tube navigation system and explore new technologies, despite a nearly 10% pre-market share drop. The company's GF Value™ suggests it is 91.4% undervalued, yet its GF Score™ of …

Earnings call transcript: QT Imaging misses Q2 2026 profit forecast

QT Imaging (QTI) reported strong Q2 2026 financial results, with revenue increasing by 103% year-over-year to $7.4 million, driven by higher scanner shipments. The company affirmed its 2026 revenue guidance of approximately $39 million, more than double the 2025 revenue, and is expanding its …

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates

Boston Scientific's CEO Bought $9M of His Own Stock

Boston Scientific's CEO, Michael Mahoney, purchased approximately $9 million of his company's stock, with two directors also buying shares and no 10b5-1 plan in place. Additionally, CoStar founder-CEO Andrew Florance bought about $2.5 million of his own stock. The article also notes that President …

Treace Medical Concepts (TMCI) CEO John T. Treace reports 19.2% beneficial stake

John T. Treace, CEO of Treace Medical Concepts, has filed an amended Schedule 13G indicating a 19.2% beneficial ownership stake in the company, totaling 12,530,959 shares. This ownership includes direct holdings, shares in family trusts, his spouse's holdings, and stock options exercisable within 60 …

Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health …

Tactile Systems Technology (TCMD): Morgan Stanley trims stake to about 3.7%

Morgan Stanley and its affiliate, Morgan Stanley Capital Services LLC, have reduced their beneficial ownership in Tactile Systems Technology Inc. (TCMD). Morgan Stanley now holds 3.7% of TCMD common stock, while Morgan Stanley Capital Services LLC holds 3.5%, with both entities reporting that they …

Tactile Systems Technology (NASDAQ:TCMD) CEO Sells $323,192.32 in Stock

Tactile Systems Technology CEO Sheri Louise Dodd sold 10,978 shares of the company's stock for $323,192.32 to cover tax obligations from vested equity awards, reducing her direct ownership by 4.5%. The company recently reported strong quarterly earnings of $0.34 EPS, surpassing analyst estimates, and …

STERIS (NYSE:STE) Director Sells $956,795.24 in Stock

STERIS (NYSE:STE) Director Mohsen Sohi sold 4,058 shares of the company's stock for a total of $956,795.24, reducing his direct holdings by 14.31% to 24,305 shares. This transaction followed the company's strong earnings report, where STERIS beat analyst EPS estimates and saw revenue rise …

908 Devices (MASS) director Brown sells 17,800 shares in Rule 10b5-1 trades

908 Devices Inc. director Christopher D. Brown sold a total of 17,800 shares of common stock in two open-market transactions on August 10 and August 11, 2026. These sales, executed under a Rule 10b5-1 trading plan adopted in November 2025, involved weighted average prices …

908 Devices (MASS) CEO Knopp sells 149K shares, reports 541K held via trust

Kevin J. Knopp, President and CEO of 908 Devices Inc. (MASS), reported selling 149,013 shares of common stock between August 10 and 12, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices ranging from $9.06 to $10.16 per share. …

Nexalin Technology (NXL) flags going concern risk as losses mount and Nasdaq warns

Nexalin Technology (NXL) reported significant losses and limited revenue for the quarter and six months ended June 30, 2026, leading management to conclude there is substantial doubt about its ability to continue as a going concern without additional funding. The company also faces a …

Nexalin Technology, Inc. 2Q 2026: Revenue $12.16K, EPS ($0.11) — 10-Q Summary

Nexalin Technology, Inc. reported its Q2 2026 results, showing a significant year-over-year revenue decline to $12.16K and an increased net loss of ($2.24M), resulting in a diluted EPS of ($0.11). The company saw a shift towards higher-margin licensing, improved gross margins, and made clinical …

Is Nortech Systems Inc (NSYS) Overvalued After Q2 Earnings? GF S

Nortech Systems Inc (NSYS) reported a 9.3% increase in net sales to $33.5 million for Q2 2026, alongside a slight rise in net income. Despite revenue growth, the company faces operational challenges with a 24.1% jump in operating expenses. GuruFocus assesses NSYS as overvalued …

Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall

MaxCyte reported Q2 2026 revenue of $7.3 million, exceeding analyst expectations, though shares fell after hours due to a year-over-year sales decline and lower margins. The company highlighted stabilization in the cell therapy market and a new enterprise partnership with Genentech as key developments. …

Lumexa: Q2 Earnings Snapshot

Lumexa Imaging Holdings Inc. (LMRI) reported Q2 earnings of $2.7 million, or 3 cents per share. Adjusted earnings were 20 cents per share, and revenue reached $264.2 million, exceeding analyst forecasts. The company projects full-year earnings between 71 cents and 77 cents per share, …

ClearPoint Neuro (CLPT): MAK Capital group discloses 7.8% ownership in 13G/A

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have filed a Schedule 13G/A, disclosing a collective beneficial ownership of 2,375,861 shares of ClearPoint Neuro, Inc. (CLPT) common stock. This represents 7.8% of the company's outstanding shares as of June 30, …

DexCom Inc. stock outperforms competitors on strong trading day

DexCom Inc. (DXCM) saw its stock rise by 1.42% to $90.80 on Wednesday, marking its fifth consecutive day of gains. This performance outpaced the broader market, as the S&P 500 Index increased by 0.26% and the Dow Jones Industrial Average fell by 0.04% on …

Lucid Diagnostics (LUCD) Releases Q2 2026 Earnings: Revenue Up 26.7% but Losses Continue

Lucid Diagnostics (LUCD) reported a 26.7% increase in Q2 2026 revenue, reaching $1.5 million, which slightly exceeded analyst expectations. Despite this top-line growth, the company continued to post significant losses, with a net loss of $14.7 million. Insider trading activity shows one purchase in …

Lumexa Imaging (NASDAQ:LMRI) Updates FY 2026 Earnings Guidance

$MXCT ($MXCT) Releases Q2 2026 Earnings

LUMEXA IMAGING HOLDINGS ($LMRI) Releases Q2 2026 Earnings, Stock Rises

Nortech Systems GAAP EPS of $0.11, revenue of $33.5M

* Nortech Systems press release [https://seekingalpha.com/pr/20617339-nortech-systems-reports-second-quarter-results] (NSYS [https://seekingalpha.com/symbol/NSYS]): Q2 GAAP EPS of $0.11. * Revenue of $33.5M (+9.1% Y/Y). MORE ON NORTECH SYSTEMS * Nortech Systems Incorporated (NSYS) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4904874-nortech-systems-incorporated-nsys-q1-2026-earnings-call-transcript] * Nortech outlines $15M asset-backed credit line as backlog reaches …

QT Imaging Reports Strong Revenue Growth Amid Ongoing Losses

Axogen Insider Sold Shares Worth $3,195,788, According to a Recent SEC Filing

An insider at Axogen (AXGN) sold shares valued at $3,195,788, as disclosed in a recent SEC filing. This transaction follows another reported insider sale of $646,592 on the same day. Axogen specializes in technologies for peripheral nerve regeneration and repair.

QT Imaging (QTI) Q2 2026 Earnings Call Transcript

QT Imaging (QTI) reported strong Q2 2026 financial results, with revenue increasing by 103% year-over-year to $7.4 million, driven by higher scanner shipments. The company affirmed its 2026 revenue guidance of approximately $39 million, more than double the 2025 revenue, and is expanding its …

12 Health Care Stocks Moving In Wednesday's After-Market Session

This article details the performance of 12 healthcare stocks during Wednesday's after-market session, categorized into gainers and losers. Notable gainers include ENvue Medical and Omeros, with Omeros reporting Q2 earnings. Significant losers include Outlook Therapeutics and Valion Bio.

STERIS plc (STE) director Holland receives 1,025 Career Restricted Stock Units

STERIS plc director Christopher S. Holland was granted 1,025 Career Restricted Stock Units (RSUs). These RSUs are fully vested immediately and represent the right to receive one ordinary share each, to be settled six months after his Board service concludes. Following this grant, Holland …

DexCom (DXCM) director Bridgette Heller sells 1,012 shares in planned trade

DexCom director Bridgette P. Heller sold 1,012 shares of common stock at $88.29 per share on August 12, 2026, as part of a pre-established Rule 10b5-1 trading plan adopted in August 2025. Following the sale, Ms. Heller directly holds 29,570 shares, which includes 5,575 …

STERIS plc (STE) director Pierre Boulud receives 1,025 Career RSUs

STERIS plc director Pierre Boulud was granted 1,025 Career Restricted Stock Units (RSUs), which are fully vested immediately but will be settled in ordinary shares six months after he ceases Board service. This grant brings his total direct RSU holdings to 1,392 units. Each …

Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load